BioLineRx Ltd. (BLRX)
2.216
+0.01
(+0.27%)
USD |
NASDAQ |
Oct 09, 16:00
2.22
0.00 (0.00%)
After-Hours: 20:00
BioLineRx Enterprise Value : 7.392M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 7.392M |
| October 08, 2026 | 7.366M |
| October 07, 2026 | 7.344M |
| October 06, 2026 | 7.725M |
| October 05, 2026 | 7.846M |
| October 02, 2026 | 8.065M |
| October 01, 2026 | 7.978M |
| September 30, 2026 | 7.978M |
| September 29, 2026 | 8.021M |
| September 28, 2026 | 8.327M |
| September 25, 2026 | 9.070M |
| September 24, 2026 | 8.720M |
| September 23, 2026 | 8.895M |
| September 22, 2026 | 8.327M |
| September 21, 2026 | 8.545M |
| September 18, 2026 | 8.576M |
| September 17, 2026 | 8.764M |
| September 16, 2026 | 8.545M |
| September 15, 2026 | 8.720M |
| September 14, 2026 | 8.327M |
| September 11, 2026 | 8.676M |
| September 10, 2026 | 8.936M |
| September 09, 2026 | 8.851M |
| September 08, 2026 | 9.026M |
| September 04, 2026 | 9.375M |
| Date | Value |
|---|---|
| September 03, 2026 | 9.463M |
| September 02, 2026 | 9.681M |
| September 01, 2026 | 9.768M |
| August 31, 2026 | 9.943M |
| August 28, 2026 | 9.070M |
| August 27, 2026 | 9.768M |
| August 26, 2026 | 9.506M |
| August 25, 2026 | 10.16M |
| August 24, 2026 | 10.82M |
| August 21, 2026 | 9.987M |
| August 20, 2026 | 9.768M |
| August 19, 2026 | 10.51M |
| August 18, 2026 | 10.16M |
| August 17, 2026 | 9.244M |
| August 14, 2026 | 9.768M |
| August 13, 2026 | 9.588M |
| August 12, 2026 | 9.463M |
| August 11, 2026 | 9.834M |
| August 10, 2026 | 9.559M |
| August 07, 2026 | 9.550M |
| August 06, 2026 | 9.900M |
| August 05, 2026 | 9.581M |
| August 04, 2026 | 9.768M |
| August 03, 2026 | 9.319M |
| July 31, 2026 | 10.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 407.84M |
| Can-Fite BioPharma Ltd. | -4.811M |
| Eocene Ltd. | -7.716M |
| Revium Recovery, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.414M |
| Revenue (Quarterly) | 0.299M |
| Total Expenses (Quarterly) | 3.377M |
| EPS Diluted (Quarterly) | -0.6957 |
| Gross Profit Margin (Quarterly) | 53.41% |
| Profit Margin (Quarterly) | -1.48K% |
| Earnings Yield | -82.09% |
| Normalized Earnings Yield | -82.19 |